+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vaccines Market - Global Forecast 2026-2032- Product Image
Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Vaccines Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985895
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vaccines Market is projected to reach USD 97.14 Billion in 2026. It is expected to continue growing at a CAGR of 7.76%, reaching USD 152.31 Billion by 2032.

Vaccines remain one of the highest-impact health technologies, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The vaccines landscape spans pediatric immunization, adult boosters, travel vaccines, maternal vaccination, therapeutic cancer vaccines, and epidemic preparedness, creating a broad industry shaped by public procurement, private innovation, and global health security needs.

Demand is being driven by routine immunization recovery after COVID-19 disruptions, rising use of newer platforms such as mRNA, viral vectors, recombinant proteins, and conjugate technologies, expanded human papillomavirus and pneumococcal programs, and stronger government stockpiling for pandemic and outbreak response. WHO and UNICEF estimates also show persistent access gaps, including 14.5 million zero-dose children in 2023, making coverage recovery and equitable delivery central to long-term vaccine strategy. For industry leaders, success depends on evidence-based portfolio prioritization, resilient supply chains, regulatory agility, and access models that improve immunization coverage while sustaining commercial performance.

Transformative Shifts in the Vaccines Landscape

The vaccine industry is shifting from a primarily pediatric and seasonal business toward a life-course immunization model. Aging populations are increasing demand for influenza, pneumococcal, shingles, respiratory syncytial virus, and COVID-19 vaccines, while maternal immunization is gaining policy support as a way to protect infants before they are eligible for direct vaccination.

Technology is also reshaping competition. mRNA platforms demonstrated global scalability during the COVID-19 response, and developers are now applying nucleic acid, recombinant protein, conjugate, viral-vector, and combination approaches to influenza, RSV, oncology, and emerging infectious disease vaccines. At the same time, governments are emphasizing domestic manufacturing, fill-finish capacity, cold-chain resilience, genomic surveillance, and faster regulatory pathways to reduce dependence on concentrated supply hubs and strengthen epidemic readiness.

Cumulative Impact of Artificial Intelligence on Vaccines

Artificial intelligence is becoming a practical accelerator across vaccine discovery, clinical development, manufacturing, and pharmacovigilance. AI-enabled antigen design, protein structure modeling, epitope prediction, and immune-response simulation can help narrow candidate selection before costly trials. In clinical operations, analytics can improve site selection, participant recruitment, protocol optimization, and real-time safety monitoring.

The cumulative impact is faster cycle times and more targeted investment decisions, but responsible adoption is essential. Vaccine developers must validate AI outputs against laboratory and clinical evidence, protect patient data, reduce model bias, and maintain transparent regulatory documentation. Used well, AI can strengthen pandemic readiness, optimize strain selection, improve demand forecasting, enhance quality control, and improve post-market signal detection without replacing established scientific and regulatory standards.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is central to vaccine growth because of its population scale, expanding middle class, large birth cohorts, and manufacturing depth in China, India, Japan, South Korea, and Australia. The region is also shaped by high infectious-disease surveillance needs, national immunization expansion, and public investment in biotechnology capacity. North America remains a leading innovation and commercialization hub, supported by the U.S. biomedical research ecosystem, advanced regulatory pathways, robust adult immunization infrastructure, and coordinated public-health guidance in the United States and Canada.

Latin America shows rising demand for pediatric, HPV, influenza, dengue, and outbreak-response vaccines, with Brazil and Mexico anchoring public immunization programs and regional manufacturing ambitions. Europe combines mature vaccination programs with strong regulatory oversight through the European Medicines Agency and national technical advisory groups, while also prioritizing adult immunization, pharmacovigilance, antimicrobial-resistance prevention through vaccination, and supply resilience following pandemic-era procurement lessons.

The Middle East is investing in health security, procurement modernization, digital immunization systems, and domestic biologics capacity, particularly across high-income Gulf markets that are expanding preventive care and travel-related vaccination infrastructure. Africa represents both an urgent coverage opportunity and a long-term manufacturing priority, as the African Union and Africa CDC support expanded local vaccine production, stronger cold-chain systems, improved last-mile delivery, and more resilient supply networks to reduce dependence on imported vaccines.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are expanding vaccine demand through sizable birth cohorts, school-based immunization programs, travel recovery, dengue prevention priorities, and stronger pandemic preparedness, while regional procurement approaches still vary widely by country income, financing structures, and health system capacity. The GCC is prioritizing immunization modernization, digital health records, life-course vaccination, and strategic purchasing, creating opportunities for adult vaccines, travel vaccines, and public-private supply partnerships.

The European Union remains influential through centralized regulatory standards, joint procurement experience, pharmacovigilance coordination, and health security planning under regional preparedness frameworks. BRICS economies combine large population needs with growing domestic manufacturing, public-sector procurement, and technology-transfer priorities, making them important for high-volume immunization delivery, localized production, and diversified global vaccine supply.

G7 countries lead in vaccine R&D financing, regulatory science, premium-market adoption, and preparedness funding, especially for adult, maternal, respiratory, and specialty vaccines. NATO members increasingly view vaccine availability as part of biodefense, military readiness, force health protection, and civil resilience, reinforcing the link between immunization, emergency preparedness, and national security.

Key Country Insights Across Major Vaccine Markets

The United States leads global vaccine innovation through deep capital markets, NIH-supported research, BARDA preparedness funding, ACIP guidance, and large commercial and public immunization channels. Canada emphasizes public procurement, national immunization guidance, and equitable access across provinces and territories, while Mexico combines public-sector demand with regional manufacturing potential and cross-border disease surveillance priorities. Brazil is a major Latin American anchor through its National Immunization Program, large public-sector purchasing role, and established public vaccine production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature vaccine markets with strong regulatory systems, adult immunization needs, public purchasing mechanisms, and established pharmacovigilance practices. The United Kingdom has a prominent national immunization advisory structure and clinical research capacity; Germany and France bring advanced biomedical ecosystems and strong public-health infrastructure; Italy and Spain continue to focus on pediatric, elderly, and regional coverage improvements. Russia maintains domestic vaccine capabilities and sovereign supply priorities. China and India are critical to global scale: China has a large domestic immunization base and expanding biotechnology capabilities, while India is one of the world’s largest vaccine suppliers by volume and a key source for routine immunization programs in low- and middle-income countries.

Japan, Australia, and South Korea are high-value Asia-Pacific vaccine markets with strong quality standards, aging populations, and active life-science ecosystems. Japan’s demographic profile supports demand for adult and elderly immunization, Australia is important for seasonal influenza surveillance and regional public-health preparedness, and South Korea is strengthening its role in advanced biomanufacturing, clinical research, and regional epidemic-response partnerships.

Actionable Recommendations for Vaccine Industry Leaders

Industry leaders should prioritize life-course immunization portfolios, including adult respiratory, maternal, adolescent, travel, and specialty vaccines, while protecting core pediatric franchises. Commercial plans should be aligned with national immunization technical advisory group evidence requirements, real-world effectiveness data, safety monitoring, and health-economic models that demonstrate avoided hospitalizations, productivity gains, and health-system savings.

Operationally, organizations should diversify antigen, adjuvant, vial, stopper, lipid nanoparticle, cold-chain, and fill-finish supply; build regional manufacturing partnerships; and invest in end-to-end supply visibility. Leaders should also embed AI governance, strengthen pharmacovigilance, support vaccine confidence campaigns, improve healthcare-provider education, and design access models for low- and middle-income countries through tiered pricing, pooled procurement, donation mechanisms, and technology transfer where appropriate.

Research Methodology

This executive summary is based on a structured review of verified public-health, regulatory, and industry evidence. Core sources include the World Health Organization, UNICEF, Gavi, the Vaccine Alliance, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization programs, public procurement documents, peer-reviewed literature, and publicly available government and institutional disclosures.

The analysis combines disease-burden trends, immunization coverage data, technology-platform developments, regulatory patterns, procurement dynamics, cold-chain requirements, and regional manufacturing priorities. Findings were synthesized to identify durable strategic themes rather than short-term fluctuations, with emphasis on evidence that is internationally recognized, reproducible, and relevant to vaccine developers, manufacturers, distributors, healthcare providers, policymakers, and investors.

Conclusion

The vaccines sector is entering a more complex but opportunity-rich phase. Routine immunization recovery, adult vaccine expansion, mRNA and recombinant-platform innovation, AI-assisted development, and health-security investment are reshaping how vaccines are discovered, manufactured, financed, regulated, and delivered.

Winning organizations will combine scientific excellence with access discipline. They will need to prove clinical value, scale reliably, navigate regional policy differences, and support public trust. As governments and healthcare systems continue to treat immunization as both preventive care and strategic preparedness, vaccines will remain central to global health outcomes and long-term life-science growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Vaccines Market, by Type
7.1. Introduction
7.2. Inactivated Vaccines
7.3. Live-Attenuated Vaccines
7.4. Messenger RNA Vaccines
7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
7.6. Toxoid Vaccines
7.7. Viral Vector Vaccines
8. Vaccines Market, by Vaccine Combination
8.1. Introduction
8.2. Mono-Valent Vaccines
8.3. Multi-Valent Vaccines
9. Vaccines Market, by Disease Indication
9.1. Introduction
9.2. Infectious Disease Vaccines
9.2.1. Influenza
9.2.2. Hepatitis A & B
9.2.3. Polio
9.2.4. COVID-19
9.2.5. Pneumococcal & Meningococcal Disease
9.2.6. Human Papillomavirus HPV
9.2.7. Rotavirus
9.2.8. Dengue
9.2.9. Malaria
9.2.10. Rabies
9.3. Non-Infectious Disease Vaccines
9.3.1. Cancer Vaccines
9.3.2. Allergy Vaccines
9.3.3. Alzheimer’s Vaccines
10. Vaccines Market, by Vaccine Classification
10.1. Introduction
10.2. Preventive Vaccines
10.3. Therapeutic Vaccines
11. Vaccines Market, by Route of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intranasal
11.4. Oral
11.5. Subcutaneous
12. Vaccines Market, by Dosage
12.1. Introduction
12.2. Multi Dose
12.3. Single Dose
13. Vaccines Market, by Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
13.4.1. Infants
13.4.2. Toddlers
14. Vaccines Market, by End User
14.1. Introduction
14.2. Academic & Research Institutes
14.3. Hospitals & Clinics
14.4. Vaccination Centers
15. Vaccines Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Vaccines Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Vaccines Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. Japan
17.5. India
17.6. United Kingdom
17.7. France
17.8. Canada
17.9. Italy
17.10. Australia
17.11. South Korea
17.12. Brazil
17.13. Mexico
17.14. Russia
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Pfizer Inc.
19.2. BioNTech SE
19.3. Sinovac Biotech Ltd.
19.4. Moderna, Inc.
19.5. Merck & Co., Inc.
19.6. GlaxoSmithKline PLC
19.7. Sanofi S.A.
19.8. Johnson & Johnson Services, Inc.
19.9. AstraZeneca PLC
19.10. Abbott Laboratories
19.11. Astellas Pharma Inc.
19.12. Bavarian Nordic A/S
19.13. Bharat Biotech Ltd.
19.14. Biological E. Limited
19.15. Blue Lake Biotechnology
19.16. Capricor Therapeutics, Inc.
19.17. Chongqing Zhifei Biological Products Co., Ltd.
19.18. CSL Limited
19.19. CureVac N.V.
19.20. Daiichi Sankyo Company, Limited.
19.21. Gennova Biopharmaceuticals Limited
19.22. Haffkine Bio-Pharmaceutical Corporation Ltd.
19.23. Incepta Pharmaceuticals Ltd.
19.24. Inovio Pharmaceuticals, Inc.
19.25. Novavax, Inc.
19.26. Serum Institute of India Pvt. Ltd.
19.27. Takeda Pharmaceutical Company Limited
19.28. VBI Vaccines Inc.
19.29. Versatope Therapeutics
19.30. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIVE-ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MESSENGER RNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TOXOID VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TOXOID VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MONO-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MULTI-VALENT VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL HEPATITIS A & B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HEPATITIS A & B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HEPATITIS A & B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POLIO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POLIO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PNEUMOCOCCAL & MENINGOCOCCAL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS HPV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DENGUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MALARIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RABIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL RABIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NON-INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ALLERGY VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ALLERGY VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ALLERGY VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ALZHEIMER’S VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL INFANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TODDLERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL TODDLERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL TODDLERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. EUROPE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. EUROPE VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 144. EUROPE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 145. EUROPE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 146. EUROPE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 147. EUROPE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 148. EUROPE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. EUROPE VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 150. EUROPE VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 151. EUROPE VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 152. EUROPE VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. AFRICA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. AFRICA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 179. AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 180. AFRICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 181. AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 182. AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 183. AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 184. AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 186. AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 187. AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 188. AFRICA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. NATO VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. NATO VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 204. NATO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 205. NATO VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 206. NATO VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 207. NATO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 208. NATO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 209. NATO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. NATO VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 211. NATO VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 212. NATO VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 213. NATO VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. G7 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. G7 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 216. G7 VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 217. G7 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 218. G7 VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 219. G7 VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 220. G7 VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 221. G7 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 222. G7 VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 223. G7 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 224. G7 VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 225. G7 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. BRICS VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 239. BRICS VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 240. BRICS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 241. BRICS VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 242. BRICS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 243. BRICS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 244. BRICS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 245. BRICS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. BRICS VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 247. BRICS VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. BRICS VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 249. BRICS VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. ASEAN VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. ASEAN VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 252. ASEAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 253. ASEAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 254. ASEAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 255. ASEAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 256. ASEAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 257. ASEAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. ASEAN VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 259. ASEAN VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. ASEAN VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 261. ASEAN VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. GCC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 263. GCC VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 264. GCC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 265. GCC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 266. GCC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 267. GCC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 268. GCC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 269. GCC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. GCC VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 271. GCC VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 272. GCC VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 273. GCC VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. CHINA VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. CHINA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 289. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 290. CHINA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 291. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 292. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 293. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 294. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. CHINA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 296. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 297. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 298. CHINA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. GERMANY VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. GERMANY VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 301. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 302. GERMANY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 303. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 304. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 305. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 306. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. GERMANY VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 308. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 309. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 310. GERMANY VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. JAPAN VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. JAPAN VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 313. JAPAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 314. JAPAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 315. JAPAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 316. JAPAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 317. JAPAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 318. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. JAPAN VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 320. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 321. JAPAN VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 322. JAPAN VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. INDIA VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. INDIA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 325. INDIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 326. INDIA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 327. INDIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 328. INDIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 329. INDIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 330. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 331. INDIA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 332. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 333. INDIA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 334. INDIA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 342. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 343. UNITED KINGDOM VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 344. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 345. UNITED KINGDOM VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 346. UNITED KINGDOM VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 347. FRANCE VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. FRANCE VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 349. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 350. FRANCE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 351. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 352. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 353. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 354. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 355. FRANCE VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 356. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 357. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 358. FRANCE VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 359. CANADA VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. CANADA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 361. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 362. CANADA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 363. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 364. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 365. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 366. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 367. CANADA VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 368. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 369. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 370. CANADA VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 371. ITALY VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 372. ITALY VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 373. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 374. ITALY VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 375. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 376. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 377. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 378. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 379. ITALY VACCINES MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 380. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 381. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2017-2032 (USD MILLION)
TABLE 382. ITALY VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 383. AUSTRALIA VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 384. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 385. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2017-2032 (USD MILLION)
TABLE 386. AUSTRALIA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 387. AUSTRALIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 388. AUSTRALIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2017-2032 (USD MILLION)
TABLE 389. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATIO

Companies Mentioned

  • Pfizer Inc.
  • BioNTech SE
  • Sinovac Biotech Ltd.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca PLC
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 97.14 Billion
Forecasted Market Value ( USD ) by 2032 $ 152.31 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Infectious Vaccines Market - Global Forecast 2026-2032 - Product Image

Infectious Vaccines Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Oral Vaccine Market - Global Forecast 2026-2032 - Product Image

Oral Vaccine Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Combination Vaccines - Global Strategic Business Report - Product Image

Combination Vaccines - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Human Vaccines - Global Strategic Business Report - Product Image

Human Vaccines - Global Strategic Business Report

  • Report
  • 448 Pages
  • Global
From
Vaccine Market Size, Share & Trends Analysis Report by Indication, Type, Route of Administration, Age Group, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Vaccine Market Size, Share & Trends Analysis Report by Indication, Type, Route of Administration, Age Group, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.